• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

9.900 +0.250 (+2.59%)
Streaming Delayed Price Updated: 11:05 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,232
Open 9.650
Bid (Size) 9.820 (100)
Ask (Size) 10.10 (100)
Prev. Close 9.650
Today's Range 9.610 - 10.49
52wk Range 3.760 - 46.31
Shares Outstanding 42,940,089
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
December 11, 2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists 
From Aligos Therapeutics
Via GlobeNewswire

Performance

YTD
+8.4%
+8.4%
1 Month
-8.2%
-8.2%
3 Month
-0.3%
-0.3%
6 Month
+14.3%
+14.3%
1 Year
-75.8%
-75.8%

More News

Read More
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
August 06, 2025
Via Benzinga
News headline image
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
November 10, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
November 06, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at Upcoming Investor Conferences
November 04, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
October 30, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 17, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
October 16, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
October 14, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
October 07, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
September 03, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
August 27, 2025
Via Benzinga
News headline image
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
August 20, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 15, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
August 13, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
August 06, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
June 18, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From Aligos Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Aligos Therapeutics, Inc. - Common stock publicly traded?
Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Aligos Therapeutics, Inc. - Common stock trade on?
Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?
The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market
What is the current price of Aligos Therapeutics, Inc. - Common stock?
The current price of Aligos Therapeutics, Inc. - Common stock is 9.900
When was Aligos Therapeutics, Inc. - Common stock last traded?
The last trade of Aligos Therapeutics, Inc. - Common stock was at 01/08/26 11:05 AM ET
What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?
The market capitalization of Aligos Therapeutics, Inc. - Common stock is 425.11M
How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?
Aligos Therapeutics, Inc. - Common stock has 425M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap